SLS

4.87

2.99% -0.15

Handel nachbörslich: 4.88 0.010 +0.21%

Sellas Life Sciences Group Inc (SLS)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt SLS? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$5.02

Offen:

$5.05

24-Stunden-Volumen:

2.84M

Relative Volume:

0.47

Marktkapitalisierung:

$898.67M

Einnahmen:

Nettoeinkommen (Verlust:

$-26.86M

KGV:

-19.81

EPS:

-0.2458

Netto-Cashflow:

$-28.39M

1W Leistung:

-0.20%

1M Leistung:

+17.92%

6M Leistung:

+189.88%

1J Leistung:

+184.80%

1-Tages-Spanne:

$4.825

$5.055

1-Wochen-Bereich:

$4.655

$5.235

52-Wochen-Spanne:

$1.36

$6.14

Sellas Life Sciences Group Inc Stock (SLS) Company Profile

Firmenname

Sellas Life Sciences Group Inc

Sektor

Healthcare (1106)

Branche

Biotechnology (615)

Telefon

(646) 200-5278

Adresse

7 TIMES SQUARE, NEW YORK, NY

Mitarbeiter

Twitter

Nächster Verdiensttermin

2026-05-12

Neueste SEC-Einreichungen

SLS's Discussions on Twitter

Compare SLS vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
SLS Sellas Life Sciences Group Inc	4.87	926.35M	0	-26.86M	-28.39M	-0.2458
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2021-07-21	Eingeleitet	Cantor Fitzgerald	Overweight
2018-11-01	Eingeleitet	Oppenheimer	Outperform
2018-04-02	Eingeleitet	H.C. Wainwright	Buy
2018-03-19	Hochstufung	Maxim Group	Hold → Buy

Sellas Life Sciences Group Inc Aktie (SLS) Neueste Nachrichten

May 05, 2026

SLS stock kicks off week in green: CEO flags role in EU biotech policy talks that could impact drug approvals - MSN

May 05, 2026

May 04, 2026

SLS Stock Kicks Off Week In Green: CEO Flags Role In EU Biotech Policy Talks That Could Impact Drug Approvals - Stocktwits

May 04, 2026

May 03, 2026

SLS stock slips after-hours as cancer pipeline silence frustrates retail — China licensing fight now in spotlight - MSN

May 03, 2026

May 02, 2026

SLS Stock Tests $5 Again: Retail Targets ‘No’ Vote On 20M Share Dilution Push Before AML Trial Results - Stocktwits

May 02, 2026

SLS stock gains momentum: NVDA, MSFT investor loads up ahead of AML trial milestone trigger - MSN

May 02, 2026

May 01, 2026

Sellas Life Sciences draws significant retail buzz as traders eye REGAL phase 3 catalyst – SLS stock soars 15% - MSN

May 01, 2026

SLS News | SELLAS LIFE SCIENCES GROUP I (NASDAQ:SLS) - ChartMill

May 01, 2026

Apr 30, 2026

SLS stock sparks retail buzz ahead of AACR presentation on experimental cancer therapy - MSN

Apr 30, 2026

SLS stock jumps premarket: US investor Dagco boosts stake by 78% ahead of fresh cancer drug data reveal - MSN

Apr 30, 2026

SLS Forecast, Price Target & Analyst Ratings | SELLAS LIFE SCIENCES GROUP I (NASDAQ:SLS) - ChartMill

Apr 30, 2026

Apr 29, 2026

SLS stock jumps overnight: ‘potent’ AML drug data ahead of cancer summit fuels fresh momentum - MSN

Apr 29, 2026

SELLAS Life Sciences Group (SLS) price target increased by 15.38% to 10.20 - MSN

Apr 29, 2026